Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer

Grunberg, 2004, Incidence of chemotherapy-induced nausea and emesis after modern antiemetics, Cancer., 100, 2261, 10.1002/cncr.20230 Ng, 2015, Chemotherapy-induced nausea and vomiting: time for more emphasis on nausea?, Oncologist, 20, 576, 10.1634/theoncologist.2014-0438 Oza, 2018, Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial, Lancet Oncol., 19, 1117, 10.1016/S1470-2045(18)30333-4 Ledermann, 2016, Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer, Br. J. Cancer, 115, 1313, 10.1038/bjc.2016.348 Friedlander, 2018, Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial, Lancet Oncol., 19, 1126, 10.1016/S1470-2045(18)30343-7 Ettinger, 2020, NCCN clinical practice guidelines in oncology: Antiemesis version 2, Natl. Compr. Cancer Care Netw. Hesketh, 2017, Antiemetics: American Society of Clinical Oncology clinical practice guideline update, J. Oncol. Pract., 13, 825, 10.1200/JOP.2017.026351 Roila, 2016, 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients, Ann. Oncol., 27, v119, 10.1093/annonc/mdw270 Aapro, 2019 Navari, 2016, Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting, N. Engl. J. Med., 374, 1356, 10.1056/NEJMra1515442 Costa, 2015, Prevention of nausea and vomiting in patients undergoing oral anticancer therapies for solid tumors, Biomed. Res. Int., 309601 Liu, 2018, Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials, Drug Des. Dev. Ther., 12, 3013, 10.2147/DDDT.S164553 Moore, 2016, Patient counseling and management of symptoms during olaparib therapy for recurrent ovarian cancer, Oncologist, 21, 954, 10.1634/theoncologist.2015-0268 Ledermann, 2012, Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer, N. Engl. J. Med., 366, 1382, 10.1056/NEJMoa1105535 Kaufman, 2015, Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation, J. Clin. Oncol., 33, 244, 10.1200/JCO.2014.56.2728 Pujade-Lauraine, 2017, Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial, Lancet Oncol., 18, 1274, 10.1016/S1470-2045(17)30469-2 Moore, 2018, Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer, N. Engl. J. Med., 379, 2495, 10.1056/NEJMoa1810858 Coleman, 2017, Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 390, 1949, 10.1016/S0140-6736(17)32440-6 Mirza, 2016, Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer, N. Engl. J. Med., 375, 2154, 10.1056/NEJMoa1611310 Moore, 2019, Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial, Lancet Oncol., 20, 636, 10.1016/S1470-2045(19)30029-4 Gonzalez-Martin, 2019, Niraparib in patients with newly diagnosed advanced ovarian cancer, N. Engl. J. Med., 10.1056/NEJMoa1910962 Oza, 2017, Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from study 10 and ARIEL2, Gynecol. Oncol., 147, 267, 10.1016/j.ygyno.2017.08.022 LaFargue, 2019, Exploring and comparing adverse events between PARP inhibitors, Lancet Oncol., 20, e15, 10.1016/S1470-2045(18)30786-1 Frey, 2017, Ovarian cancer survivors’ acceptance of treatment side effects evolves as goals of care change over the cancer continuum, Gynecol. Oncol., 146, 386, 10.1016/j.ygyno.2017.05.029 Herzog, 2017, FDA ovarian cancer clinical trial endpoints workshop: a Society of Gynecologic Oncology White Paper, Gynecol. Oncol., 147, 3, 10.1016/j.ygyno.2017.08.012 Davis-Perry, 2003, Melphalan for the treatment of patients with recurrent epithelial ovarian cancer, Am. J. Clin. Oncol., 26, 429, 10.1097/01.COC.0000027269.06091.E9 AstraZeneca Pharmaceuticals, 2017 Clovis Oncology Inc, 2016 Tesaro Inc, 2017 Raftopoulos, 2015, Support Care Cancer, 23, 723, 10.1007/s00520-014-2400-3 Seol, 2016, Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study, Support Care Cancer, 24, 945, 10.1007/s00520-015-2865-8 Armbruster, 2020, A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation [published online ahead of print, 2020 Apr 27], Support Care Cancer Sutherland, 2018, Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults, Cochrane Database Syst Rev., 9 Navari, 2013, The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, Support Care Cancer, 21, 1655, 10.1007/s00520-012-1710-6 Navari, 2020, Olanzapine for the treatment of advanced Cancer-related chronic nausea and/or vomiting: a randomized pilot trial [published online ahead of print, 2020 may 7], JAMA Oncol., 6, 1 Gunderson, 2018, Management of the toxicities of common targeted therapeutics for gynecologic cancers, Gynecol. Oncol., 148, 591, 10.1016/j.ygyno.2018.01.010 National Comprehensive Care Network National Cancer Institute Drew, 2020, Real-world delivery of Rucaparib to patients with ovarian cancer: recommendations based on an integrated safety analysis of ARIEL2 and study 10, Oncologist, 25, e109, 10.1634/theoncologist.2019-0229 Navari, 2018, Managing nausea and vomiting in patients with cancer: what works, Oncology (Williston Park), 32 Wood, 2011, Tools for assessing nausea, vomiting, and retching, Cancer Nurs., 34, E14, 10.1097/NCC.0b013e3181e2cd79 Molassiotis, 2007, Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC Antiemesis tool, J. Pain Symptom Manag., 34, 148, 10.1016/j.jpainsymman.2006.10.018 Kluetz, 2016, vol. 36, 67 National Cancer Institute, 2017